| scholarly article | Q13442814 |
| P50 | author | Sandra Rayego-Mateos | Q59704892 |
| Ana B Sanz | Q63413139 | ||
| Raul Rodrigues-Diez | Q87951751 | ||
| Pierre-Louis Tharaux | Q48189014 | ||
| Carlos López-Larrea | Q51888859 | ||
| Marta Ruiz-Ortega | Q56616783 | ||
| P2093 | author name string | Alberto Ortiz | |
| Jesus Egido | |||
| Pablo Cannata-Ortiz | |||
| Beatriz Suarez-Alvarez | |||
| Ramon M Rodriguez | |||
| José Luis Morgado-Pascual | |||
| P2860 | cites work | Brd4 maintains constitutively active NF-κB in cancer cells by binding to acetylated RelA | Q24293271 |
| Selective inhibition of BET bromodomains | Q24301009 | ||
| Brd4 recruits P-TEFb to chromosomes at late mitosis to promote G1 gene expression and cell cycle progression | Q24301464 | ||
| Brd4 coactivates transcriptional activation of NF-kappaB via specific binding to acetylated RelA | Q24310313 | ||
| Histone recognition and large-scale structural analysis of the human bromodomain family | Q24310431 | ||
| The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription | Q24316236 | ||
| Suppression of inflammation by a synthetic histone mimic | Q27665789 | ||
| Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia | Q27674674 | ||
| Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources | Q27860739 | ||
| Linear models and empirical bayes methods for assessing differential expression in microarray experiments | Q27860758 | ||
| BRD4 is an atypical kinase that phosphorylates serine2 of the RNA polymerase II carboxy-terminal domain | Q28116760 | ||
| The mechanisms behind the therapeutic activity of BET bromodomain inhibition | Q28241504 | ||
| BET bromodomain inhibition as a therapeutic strategy to target c-Myc | Q28247024 | ||
| Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4 | Q28267929 | ||
| lumi: a pipeline for processing Illumina microarray | Q29614924 | ||
| RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia | Q29617201 | ||
| Selective inhibition of tumor oncogenes by disruption of super-enhancers | Q29617301 | ||
| Gene activation by histone and factor acetyltransferases | Q33680840 | ||
| DNA hypermethylation and DNA hypomethylation is present at different loci in chronic kidney disease | Q33740666 | ||
| An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia | Q33864145 | ||
| Role of BRD4 in hematopoietic differentiation of embryonic stem cells. | Q34000419 | ||
| Selective inhibition of CD4+ T-cell cytokine production and autoimmunity by BET protein and c-Myc inhibitors | Q34295282 | ||
| BET bromodomains mediate transcriptional pause release in heart failure | Q34361491 | ||
| BET bromodomain inhibition suppresses TH17-mediated pathology | Q34375887 | ||
| Role of SWI/SNF in acute leukemia maintenance and enhancer-mediated Myc regulation | Q34388531 | ||
| Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer | Q34416771 | ||
| Epigenetics in kidney development and renal disease | Q34633331 | ||
| RORγt-specific transcriptional interactomic inhibition suppresses autoimmunity associated with TH17 cells | Q34831560 | ||
| An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma | Q34926232 | ||
| The Brd4 extraterminal domain confers transcription activation independent of pTEFb by recruiting multiple proteins, including NSD3. | Q35096586 | ||
| Epidermal growth factor receptor promotes glomerular injury and renal failure in rapidly progressive crescentic glomerulonephritis | Q35404631 | ||
| Therapeutic targeting of BET bromodomain protein, Brd4, delays cyst growth in ADPKD. | Q35766387 | ||
| Recent developments in epigenetics of acute and chronic kidney diseases | Q35909055 | ||
| BET protein function is required for inflammation: Brd2 genetic disruption and BET inhibitor JQ1 impair mouse macrophage inflammatory responses. | Q36718203 | ||
| Induction and effector functions of T(H)17 cells. | Q37194494 | ||
| Inflammatory signalling as mediator of epigenetic modulation in tissue-specific chronic inflammation | Q37269787 | ||
| Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer | Q37338486 | ||
| Bromodomain and extraterminal (BET) protein inhibition suppresses human T cell leukemia virus 1 (HTLV-1) Tax protein-mediated tumorigenesis by inhibiting nuclear factor κB (NF-κB) signaling | Q37388856 | ||
| Beyond genetics: epigenetic code in chronic kidney disease | Q37402757 | ||
| Interleukin-1 accounts for intrarenal Th17 cell activation during ureteral obstruction. | Q37553560 | ||
| NF-kappaB in renal inflammation | Q37774798 | ||
| The emergence of TH17 cells as effectors of renal injury. | Q37834852 | ||
| Chemokines in renal injury. | Q37862893 | ||
| Unilateral ureteral obstruction: beyond obstruction. | Q38144939 | ||
| Small molecule inhibitors of histone acetyltransferases and deacetylases are potential drugs for inflammatory diseases. | Q38165621 | ||
| TNF receptors: signaling pathways and contribution to renal dysfunction | Q38241605 | ||
| Interleukin-17 and innate immunity in infections and chronic inflammation | Q38496581 | ||
| Inhibition of bromodomain and extra-terminal proteins (BET) as a potential therapeutic approach in haematological malignancies: emerging preclinical and clinical evidence | Q38542092 | ||
| Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis | Q39238937 | ||
| Differential regulation of NF-kappaB by elongation factors is determined by core promoter type | Q40133041 | ||
| Effect of simultaneous blockade of AT1 and AT2 receptors on the NFkappaB pathway and renal inflammatory response. | Q40562942 | ||
| Targeting bromodomain-containing protein 4 (BRD4) benefits rheumatoid arthritis | Q40817673 | ||
| BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism. | Q41641646 | ||
| Brd4 is on the move during inflammation | Q41773632 | ||
| NF-κB directs dynamic super enhancer formation in inflammation and atherogenesis | Q41971115 | ||
| BET acetyl-lysine binding proteins control pathological cardiac hypertrophy | Q42709887 | ||
| Assessment of Brd4 inhibition in idiopathic pulmonary fibrosis lung fibroblasts and in vivo models of lung fibrosis | Q42710737 | ||
| Histone H3 lysine 4 monomethylation (H3K4me1) and H3 lysine 9 monomethylation (H3K9me1): distribution and their association in regulating gene expression under hyperglycaemic/hyperinsulinemic conditions in 3T3 cells | Q42831103 | ||
| NF-kappaB binds P-TEFb to stimulate transcriptional elongation by RNA polymerase II. | Q43730164 | ||
| Angiotensin II, via AT1 and AT2 receptors and NF-kappaB pathway, regulates the inflammatory response in unilateral ureteral obstruction. | Q44903329 | ||
| Integrin-linked kinase plays a key role in the regulation of angiotensin II-induced renal inflammation. | Q44963993 | ||
| The bromodomain protein inhibitor I-BET151 suppresses expression of inflammatory genes and matrix degrading enzymes in rheumatoid arthritis synovial fibroblasts. | Q48248907 | ||
| The C-terminal module IV of connective tissue growth factor is a novel immune modulator of the Th17 response. | Q51016267 | ||
| P4510 | describes a project that uses | limma | Q112236343 |
| P433 | issue | 2 | |
| P304 | page(s) | 504-519 | |
| P577 | publication date | 2016-07-19 | |
| P1433 | published in | Journal of the American Society of Nephrology | Q17123893 |
| P1476 | title | Inhibition of Bromodomain and Extraterminal Domain Family Proteins Ameliorates Experimental Renal Damage | |
| P478 | volume | 28 |
| Q59329999 | (+)-JQ1 attenuated LPS-induced microglial inflammation via MAPK/NFκB signaling |
| Q91740101 | A journey from microenvironment to macroenvironment: the role of metaflammation and epigenetic changes in cardiorenal disease |
| Q38760291 | BET Proteins: An Approach to Future Therapies in Transplantation. |
| Q39442981 | BRD4 inhibition for the treatment of pathological organ fibrosis |
| Q55316265 | Benefit of Apabetalone on Plasma Proteins in Renal Disease. |
| Q28817822 | Brd4 inhibition attenuates unilateral ureteral obstruction-induced fibrosis by blocking TGF-β-mediated Nox4 expression |
| Q60054289 | Bromodomain protein inhibition: a novel therapeutic strategy in rheumatic diseases |
| Q92253374 | Bromodomain-containing protein 4 contributes to renal fibrosis through the induction of epithelial-mesenchymal transition |
| Q33751386 | Chemical probes targeting epigenetic proteins: Applications beyond oncology |
| Q91992554 | Emerging strategies to disrupt the central TGF-β axis in kidney fibrosis |
| Q97418282 | Enhancer and super-enhancer dynamics in repair after ischemic acute kidney injury |
| Q60957108 | Epigenetic Modification Mechanisms Involved in Inflammation and Fibrosis in Renal Pathology |
| Q90399965 | Interleukin 17A Participates in Renal Inflammation Associated to Experimental and Human Hypertension |
| Q54111513 | Interleukin-1β Activates a MYC-Dependent Metabolic Switch in Kidney Stromal Cells Necessary for Progressive Tubulointerstitial Fibrosis. |
| Q37688355 | Pharmacological targeting of BET proteins inhibits renal fibroblast activation and alleviates renal fibrosis |
| Q54978951 | Protective effect of the BET protein inhibitor JQ1 in cisplatin-induced nephrotoxicity. |
| Q44011765 | Regulation of angiotensin II actions by enhancers and super-enhancers in vascular smooth muscle cells. |
| Q89723568 | Targeting the progression of chronic kidney disease |
| Q92062125 | The Contribution of Histone Crotonylation to Tissue Health and Disease: Focus on Kidney Health |
Search more.